TB-500: A Fragment of a Larger Repair Protein

The short version

TB-500 is a lab-made, seven-amino-acid peptide (Ac-LKKTETQ) built to match a small piece — residues 17 to 23 — of a much larger natural protein called thymosin beta-4. That larger protein helps cells move and rebuild tissue after injury by regulating the internal scaffolding (actin) that gives cells their shape and lets them migrate. TB-500 is not approved for any human use, is prohibited in competitive sport, and has no completed controlled human trial of its own.

Most of the encouraging findings people cite for TB-500 actually come from studies of the full-length protein, not the short fragment sold under this name — an identity gap the research literature flags directly. This page separates what has been shown for the fragment from what has only been shown for its larger parent.

What it is

TB-500 is a synthetic, N-terminally acetylated heptapeptide — Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln — corresponding to residues 17-23 of the 43-amino-acid protein thymosin beta-4 (gene TMSB4X, roughly 4963 Da). That short LKKTETQ stretch is the conserved actin-binding motif shared across the beta-thymosin protein family.

This identity issue runs through the entire TB-500 literature: in commerce, and in most published efficacy work, 'TB-500' and full-length thymosin beta-4 are treated as interchangeable, but they are not the same molecule. The fragment is roughly one-fifth the size of the parent protein. Whether the isolated 7-mer reproduces the full protein's effects at the concentrations used in research settings has not been established in controlled human trials.

How it works

Full-length thymosin beta-4 is the major actin-sequestering peptide inside cells: it binds monomeric (globular) actin one-to-one, capping both ends of the actin molecule to hold a buffered reserve of unpolymerized actin, which in turn regulates how cells change shape, move, and migrate. Structural work using X-ray crystallography confirmed this 1:1 capping mechanism at 2 Å resolution, identifying the WH2 actin-interacting motif as the structural basis ^[12].

In injury models, this actin-regulating function is linked to a cluster of downstream effects: faster cell migration, new blood-vessel growth, reduced scar (myofibroblast) formation, and anti-inflammatory, anti-apoptotic signaling as the protein is released by platelets and macrophages at the injury site ^[10]. The LKKTETQ fragment — TB-500 — is reasoned to carry the actin-binding activity specifically, but almost none of the injury-model evidence was generated with the isolated fragment itself.

What the research shows

Regulatory framing (2026). A narrative review of approved and unapproved peptide therapies for musculoskeletal injury and athletic performance — which lists TB-500/thymosin beta-4 alongside other unapproved peptides — concludes that many show favorable tissue-repair outcomes in animal models, but that rigorous human safety data are scarce, with potential for serious harm, and that these compounds operate largely outside regulatory oversight ^[8].

Stroke dose-response study (2014). In male rats with embolic middle-cerebral-artery occlusion, intraperitoneal thymosin beta-4 (2, 12, or 18 mg/kg, starting 24 hours after stroke and then every 3 days for 4 more doses) improved neurological function at the 2 mg/kg and 12 mg/kg doses, significant from day 14 through day 56 (p<0.05). The 18 mg/kg dose gave no significant benefit, and a modeled optimal dose of roughly 3.75 mg/kg was proposed — a non-monotonic result that runs against a simple more-is-better assumption ^[9].

Mechanism review (2012). A review consolidates thymosin beta-4's actin-binding, cell-mobilization, and stem-cell-activating roles; documents that it decreases myofibroblast numbers (reducing scar formation); is released by platelets and macrophages after injury to limit apoptosis, inflammation, and microbial growth; and promotes angiogenesis — the mechanistic basis for clinical trials in dermal wounds, corneal injury, and heart and CNS repair ^[10].

Phase 1 human safety study (2010). In a randomized, placebo-controlled trial, synthetic thymosin beta-4 given intravenously to 40 healthy volunteers (four cohorts of 10), as a single dose and then daily for 14 days at 42, 140, 420, or 1260 mg, was well tolerated, with only infrequent mild-to-moderate adverse events and no dose-limiting toxicities or serious adverse events. Pharmacokinetics were dose-proportional, with half-life increasing at higher doses ^[11]. This trial used the full-length protein administered intravenously, not the TB-500 fragment.

Structural biology (2004). X-ray crystallography of a gelsolin-domain-1–thymosin beta-4 hybrid bound to actin, resolved at 2 Å, established that thymosin beta-4 forms a 1:1 complex with monomeric actin and sequesters it by capping both ends, driven by the WH2 actin-interacting motif ^[12] — the structural basis for the actin-buffering mechanism the fragment is presumed to share.

Reported effects, cautions & safety

People using TB-500 in research-use communities describe a fairly consistent pattern of effects. These are compiled from online forums and community write-ups and are anecdotal, not clinical evidence — there is no completed controlled human trial of the fragment behind any of it.

Reported benefits: Faster recovery from tendon, ligament, and muscle injuries is the primary reason people in these communities describe reaching for TB-500, with less joint pain and stiffness and better range of motion frequently mentioned alongside it. Some describe improved overall flexibility during training, a general sense of reduced inflammation or calmer soreness, and occasionally better wound or skin healing. A small minority report hair regrowth, usually alongside other interventions.

Reported adverse effects: Injection-site redness, swelling, or aching is by far the most common complaint — typical of injected peptides generally, not specific to TB-500. Temporary tiredness or lethargy, especially early in a protocol, is frequently mentioned. Less commonly reported are head rush or lightheadedness, a brief flu-like feeling, nausea, a heightened awareness of an existing injury, and short-lived low mood.

Cited cautions from the literature:

• Human safety in people is essentially unstudied. No completed controlled human trials of the TB-500 heptapeptide exist for any use. A 2026 review of unapproved musculoskeletal peptides concluded that compounds like TB-500 show animal-model promise but scarce human safety data, real potential for serious harm, and operation largely outside regulatory oversight ^[8][11].
• A theoretical cancer and tumor-growth concern exists, since the parent protein is overexpressed in several cancers and linked to tumor spread and to the new blood-vessel growth that feeds tumors — the same pro-migration, pro-angiogenic actions proposed for tissue repair.
• TB-500 is prohibited in competitive sport ^[8]. It is banned by the World Anti-Doping Agency, and anti-doping laboratories have developed detection methods for it and its breakdown products.
• Reported benefits may overstate actual function. In dystrophin-deficient mice, long-term thymosin beta-4 increased the number of regenerating muscle fibers but did not improve muscle strength, heart function, or fibrosis — more regeneration on paper did not translate into better function.
• TB-500 is a fragment, not the full protein, and almost all of the encouraging efficacy research used the much larger whole protein. Applying the parent protein's results to the short fragment is an extrapolation that remains unconfirmed ^[10].
• Research-grade product quality is not guaranteed. Identity, purity, and exact sequence can vary between suppliers, adding an unpredictable variable on top of the peptide's own uncertain effects.
• Bleeding, surgery, and clotting risk is a theoretical, mechanism-based concern, given the parent protein's role in blood-vessel formation and its release by platelets at injury sites — this has not been studied for TB-500 in humans.
• Pregnancy, breastfeeding, and use in the young are precautionary exclusions, since TB-500 acts on basic developmental processes like cell movement and new blood-vessel growth, with no human safety data in these populations.

Where it fits in Recovery & Tissue Repair

TB-500 is the cell-migration member of this briefing — reasoned, via its parent protein, to help cells move into and remodel an injury site. It has none of GHK-Cu's dermatological human-trial base and none of Wolverine's combination-specific marketing; what it has is a single well-conducted human safety study, but for a different, full-length molecule ^[11]. Wolverine inherits TB-500's identity gap and adds a second, unstudied combination on top of it; GHK-Cu sits at the opposite end of the evidence spectrum, with matrix-level human data TB-500 lacks entirely. See the comparison page for the full picture.